MWNA
RCUS icon

Marshall Wace North America’s Arcus Biosciences RCUS Stock Holding History

Marshall Wace North America’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-117,962
Closed -$3.31M – 1715
2021
Q1 		$3.31M Sell
117,962
-32,264
-21% -$1.12M 0.01% 662
2020
Q4 		$3.9M Sell
150,226
-275,278
-65% -$6.66M 0.02% 597
2020
Q3 		$7.29M Buy
+425,504
New +$9.51M 0.05% 328
2020
Q2 		– Sell
-8,331
Closed -$116K – 1419
2020
Q1 		$116K Buy
+8,331
New +$104K ﹤0.01% 979
2018
Q2 		– Sell
-103,854
Closed -$1.6M – 1632
2018
Q1 		$1.6M Buy
+103,854
New +$1.73M 0.01% 867

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Marshall Wace North America's RCUS Position: Q2 2021 in Review

Marshall Wace North America sold out of Arcus Biosciences (RCUS) in Q2 2021, closing a stake of 117,962 shares — an estimated $3.31M sold.

Marshall Wace North America first reported a position in RCUS in Q1 2018 and held it in 5 quarters. The position peaked at $7.29M in Q3 2020. 130 funds tracked by Wall St. Rank hold RCUS as of Q2 2021.

  • Marshall Wace North America reported no remaining Arcus Biosciences position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 117,962 Arcus Biosciences shares in Q2 2021, an estimated $3.31M.
  • Marshall Wace North America first reported a position in Arcus Biosciences in Q1 2018 and held it in 5 quarters.
  • Marshall Wace North America's Arcus Biosciences position peaked at $7.29M in Q3 2020.
  • 130 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.